Target intelligence / Profile preview

Staphylococcal peptidoglycan pentaglycine cross-bridge ((Gly)5 bridge)

Target
(Gly)5 bridge
Molecular classification
Peptidoglycan component, Bacterial cell wall structural element
01

Overview

The staphylococcal peptidoglycan pentaglycine cross-bridge is a specialized structural component of the cell wall in Staphylococcus aureus and certain other staphylococci (Schleifer and Kandler, 1972). It is composed of five glycine residues that form a bridge between the L-lysine of one peptidoglycan stem peptide and the D-alanine of another, facilitating extensive cross-linking of the glycan strands (Rohrer et al., 1999). This structure is essential for maintaining the mechanical integrity and osmotic stability of the bacterial cell. Because this specific pentaglycine motif is unique to staphylococci, it represents a highly selective target for antimicrobial therapy. The enzyme lysostaphin, a glycylglycine endopeptidase, specifically cleaves these bridges, leading to rapid bacterial lysis and death (Bastos et al., 2010). Research also focuses on inhibiting the Fem (factor essential for methicillin resistance) protein family, which catalyzes the assembly of the pentaglycine bridge, as a strategy to restore antibiotic sensitivity in resistant strains (Ehlert et al., 1997).

Other names
Pentaglycine interpeptide bridgePentaglycine cross-linkStaphylococcal peptidoglycan bridge(Gly)5 interpeptide bridge
02

Mechanism of action

Lysostaphin acts as a glycylglycine endopeptidase that specifically cleaves the pentaglycine cross-bridges, leading to bacterial cell lysis (Bastos et al., 2010). Fem inhibitors block the enzymes responsible for the sequential addition of glycine residues to the peptidoglycan precursor (Rohrer et al., 1999).

03

Biological functions

Cell wall structural integrityOsmotic pressure resistancePeptidoglycan cross-linking
04

Disease associations

Staphylococcal infectionMethicillin-resistant Staphylococcus aureus (MRSA) infection
05

Safety considerations

Immunogenicity of lysostaphin (Walsh et al., 2003)Development of resistance via Fem gene mutations (Ehlert et al., 1997)Pro-inflammatory response from rapid bacterial lysis (Bastos et al., 2010)
06

Interacting drugs

Lysostaphin

3 more in the full profile.

07

Biomarkers

Peptidoglycan cross-linking densityBacterial loadAnti-lysostaphin antibody titers

Beyond the preview

Go deeper on Staphylococcal peptidoglycan pentaglycine cross-bridge ((Gly)5 bridge).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcal peptidoglycan pentaglycine cross-bridge ((Gly)5 bridge).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call